PD-L1/PD-1 blockage enhanced the cytotoxicity of natural killer cell on the non-small cell lung cancer (NSCLC) by granzyme B secretion

被引:8
作者
Qiao, Duan-Rui [1 ,2 ]
Cheng, Jun-Ya [1 ,2 ]
Yan, Wei-Qun [1 ]
Li, Hai-Jun [2 ,3 ]
机构
[1] Jilin Univ, Pharm Sch, Dept Bioengn, Changchun 130021, Jilin, Peoples R China
[2] Jilin Univ, Hosp 1, Inst Translat Med, Changchun 130021, Jilin, Peoples R China
[3] Jilin Univ, Hosp 1, Inst Liver Dis, Changchun, Jilin, Peoples R China
基金
中国国家自然科学基金;
关键词
PD-L1; PD-1; NK cells; Non-small cell lung cancer; Granzyme B; IMMUNOTHERAPY; PATHWAYS; CHEMOTHERAPY; EXPRESSION; ANTI-PD-L1; RECEPTORS; SUBSETS; DEATH;
D O I
10.1007/s12094-023-03120-w
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
ObjectiveTo explore the role of PD-L1/PD-1 blockage in the cytotoxicity of natural killer cell in NSCLC.MethodsTwo NSCLC cell lines, Calu-1 and H460, were tested for susceptibility to the cytolytic activity of freshly isolated healthy donor NK cells by a non-radioactive cellular cytotoxicity assay kit. Western blot analysis, FACS, ELISA and antibody blockage experiments were conducted to determine the mechanisms. NK cells isolated from NSCLC patients were also collected for functional assays.ResultsCalu-1 and H460 cells were lysed by NK cells in a dose-dependent manner. H460 cells showed less susceptibility to NK cell-mediated lysis than Calu-1 cells at all ratios. The expression of PD-L1 on H460 cells was higher than that on Calu-1 cells, as determined by FACS and western blot analysis. The specific lysis of H460 cells by NK cells was enhanced when the PD-L1/PD-1 interaction was blocked by anti-PD-L1 antibody. This finding was also demonstrated in NK cells isolated from NSCLC patients.ConclusionsThe present study revealed that PD-L1/PD-1 blockage enhanced the cytotoxicity of natural killer cells in NSCLC via granzyme B secretion. This study will greatly facilitate the precise treatment of lung cancer through determination of PD-L1 expression in tumors.
引用
收藏
页码:2373 / 2383
页数:11
相关论文
共 39 条
[1]   Recent Advances in Immunotherapy in Metastatic NSCLC [J].
Bansal, Pranshu ;
Osman, Diaa ;
Gan, Gregory N. ;
Simon, George R. ;
Boumber, Yanis .
FRONTIERS IN ONCOLOGY, 2016, 6
[2]   The B7 family of ligands and its receptors: New pathways for costimulation and inhibition of immune responses [J].
Carreno, BM ;
Collins, M .
ANNUAL REVIEW OF IMMUNOLOGY, 2002, 20 :29-53
[3]   Strategic targeting of non-small-cell lung cancer utilizing genetic material-based delivery platforms of nanotechnology [J].
Chaudhary, Swati ;
Singh, Amit ;
Kumar, Pankaj ;
Kaushik, Mahima .
JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY, 2021, 35 (07)
[4]   PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies [J].
Chen, Benjamin J. ;
Chapuy, Bjoern ;
Jing Ouyang ;
Sun, Heather H. ;
Roemer, Margaretha G. M. ;
Xu, Mina L. ;
Yu, Hongbo ;
Fletcher, Christopher D. M. ;
Freeman, Gordon J. ;
Shipp, Margaret A. ;
Rodig, Scott J. .
CLINICAL CANCER RESEARCH, 2013, 19 (13) :3462-3473
[5]   Molecular Pathways: Next-Generation Immunotherapy-Inhibiting Programmed Death-Ligand 1 and Programmed Death-1 [J].
Chen, Daniel S. ;
Irving, Bryan A. ;
Hodi, F. Stephen .
CLINICAL CANCER RESEARCH, 2012, 18 (24) :6580-6587
[6]   Report of incidence and mortality in China cancer registries, 2009 [J].
Chen, Wanqing ;
Zheng, Rongshou ;
Zhang, Siwei ;
Zhao, Ping ;
Li, Guanglin ;
Wu, Lingyou ;
He, Jie .
CHINESE JOURNAL OF CANCER RESEARCH, 2013, 25 (01) :10-21
[7]   NK cell-based immunotherapy for malignant diseases [J].
Cheng, Min ;
Chen, Yongyan ;
Xiao, Weihua ;
Sun, Rui ;
Tian, Zhigang .
CELLULAR & MOLECULAR IMMUNOLOGY, 2013, 10 (03) :230-252
[8]  
Cho Duck, 2011, Korean J Hematol, V46, P3, DOI 10.5045/kjh.2011.46.1.3
[9]   Death by a thousand cuts: Granzyme pathways of programmed cell death [J].
Chowdhury, Dipanjan ;
Lieberman, Judy .
ANNUAL REVIEW OF IMMUNOLOGY, 2008, 26 :389-420
[10]   The biology of human natural killer-cell subsets [J].
Cooper, MA ;
Fehniger, TA ;
Caligiuri, MA .
TRENDS IN IMMUNOLOGY, 2001, 22 (11) :633-640